21Shares Files Amended S-1 for Spot Injective ETF on Nasdaq

21Shares has filed an amended registration statement with the U.S. Securities and Exchange Commission to list a spot Injective exchange-traded fund on Nasdaq, updating a product that would hold the INJ token and trade under the proposed ticker TINJ. The S-1/A, filed with the SEC on September 18, is the first amendment to a registration the asset manager originally submitted in October 2025 and adds fresh detail to a widening race to bring altcoin ETFs to U.S. markets.

What the Amended Filing Details

According to the preliminary prospectus, the 21Shares Injective ETF is a passive investment vehicle structured to track the price of INJ, the native token of the Injective Network, without the use of leverage or derivatives. 21Shares US LLC acts as sponsor, with CSC Delaware Trust Company as trustee. The trust would hold INJ through two custodians, Coinbase Custody Trust Company and BitGo Bank and Trust, and price its benchmark through FTSE International Limited using a volume-weighted average across qualifying INJ spot markets. The prospectus also leaves room for the sponsor to stake a portion of the trust’s INJ where it judges the move carries no undue legal or regulatory risk.

Injective’s Push Toward Institutional Reach